Stock code: 688202 Stock abbreviation: Medicilon Announcement No.: 2025-008

Shanghai Medicililon Biopharmaceutical Co., Ltd

2024 Annual Results Forecast

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

According to the preliminary calculation of the financial department of Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), it is expected that there will be a loss in 2024, and the company's net profit attributable to shareholders of the listed company will be -347 million yuan to -232 million yuan, a decrease of 198.79 million yuan to 313.79 million yuan compared with the same period last year (statutory disclosure data).

It is estimated that the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2024 will be -367 million yuan to -245 million yuan, a decrease of 187.38 million yuan to 309.38 million yuan compared with the same period last year (statutory disclosure data).

1. Forecast of performance for the current period

(1) The performance forecast period

January 1, 2024 to December 31, 2024.

(2) Performance forecast

The preliminary calculation of the financial department is as follows:

(1) It is expected that the net profit attributable to shareholders of the listed company in 2024 will be -347 million yuan to -232 million yuan, a decrease of 198.79 million yuan to 313.79 million yuan compared with the same period last year (statutory disclosure data).

(2) It is estimated that the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2024 will be -367 million yuan to -245 million yuan, a decrease of 187.38 million yuan to 309.38 million yuan compared with the same period last year (statutory disclosure data).

(3) This performance forecast has not been audited by a certified public accountant.

Second, the performance of the same period last year

(1) Total profit: -59.105 million yuan. The net profit attributable to shareholders of the listed company was -33.2106 million yuan, and the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -57.6161 million yuan.

(2) Earnings per share: -0.26 yuan/share.

3. The main reasons for the change in the performance of the current period

During the reporting period, the main reasons for the decrease in net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses compared with the same period last year were:

(1) During the reporting period, affected by the slowdown in investment and financing in the pharmaceutical industry, market demand has changed greatly, competition in the domestic industry has intensified, and the company's operating income has declined. Although the company strictly controls various costs and expenses, it is difficult to keep pace with the decline in revenue in the short term, resulting in a decline in overall profitability.

(2) At the end of the reporting period, affected by the macroeconomic and market environment, the company made impairment losses or estimated liabilities on relevant accounts receivable, long-term assets, inventories, contract orders, etc. in accordance with the requirements of the accounting standards for business enterprises out of the principle of prudence, which was larger than the same period last year, which had a negative impact on the net profit of the current period.

4. Risk Warning

This performance forecast is a preliminary accounting conducted by the financial department based on its own professional judgment, and has not been audited by a certified public accountant. The Company has not identified any significant uncertainties affecting the accuracy of the content of this earnings forecast.

5. Other explanatory matters

The above forecast data is only preliminary accounting data, and the specific and accurate financial data are subject to the audited 2024 annual report officially disclosed by the company.

The announcement is hereby made.

Board of Directors of Shanghai Medicilon Biopharmaceutical Co., Ltd

January 18, 2025